Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 11.24 percent increase over losses of $(0.89) per share from the same period last year.
Elon Musk Could Spin Off Starlink From SpaceX And Take It Public By 2025, Says Analyst: ‘It Makes Perfect Sense’
SpaceX CEO Elon Musk, who also heads Tesla Inc (NASDAQ: TSLA), could hold an initial public offering for Starlink by 2025.
